111 results about "Autoimmunity" patented technology

This invention provides a kit for detecting anti-peroxidase-1-IgG antibodies, comprising the antigen protein peroxiredoxin-1 (peroxidase-1), a solid-phase carrier, labeled antibody, antigen dilution buffer, sample dilution buffer, antibody dilution buffer, substrate chromogenic agent, washing buffer, standards, positive control, and negative control. This kit utilizes an indirect reaction principle combined with magnetic microparticle chemiluminescence immunoassay to detect anti-peroxidase-1-IgG antibodies in the serum of the test sample. This invention is the first to identify autoantibodies against the target antigen peroxidase-1 in the serum of patients with autoimmune nephrotic syndrome. The provided kit provides a basis for domestic and international research on the molecular mechanisms and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to peroxidase-1 and peroxidase-1-IgG autoantibodies.

The present invention provides novel drug-linker conjugates and antibody-drug conjugates of imidazo quinoline amine derivatives, which have agonistic activity against Toll-like receptors (TLRs), in particular TLR7 and / or TLR8, also provided are pharmaceutical compositions and methods of treatment against certain diseases or conditions mediated by or associated with TLR7 and / or TLR8 (e.g., graft rejection, autoimmunity, inflammation, allergy, asthma, infection, sepsis, cancer, and immunodeficiency).

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

Cyclopropyl N-[(S)-[3-[1-(2,2-difluoropropylcarbamoyl)-3-hydroxy-3-methyl- cyclobutyl]imidazo[1,2-b][1,2,4]triazin-6-yl]-[4- (trifluoromethyl)cyclohexyl]methyl]carbamate, or a pharmaceutically acceptable salt thereof, being a potent modulator of human IL-17 activity, is accordingly of benefit in the treatment and / or prevention of various human ailments, including inflammatory and autoimmune disorders.

The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors which drive transient and / or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), which provide a therapeutic effect without therapy-associated toxicity. The invention further relates to related products and an animal model of aPAP.

Provided herein are bispecific antibodies and antibody fragments that bind to both human TNFRSF25 and Α4Β7. Methods of treating or preventing diseases or disorders associated with inflammation and / or autoimmunity are provided, comprising administering to a patient in need thereof an effective amount of a human TNFRSF25- and Α4Β7-binding bispecific antibody.

Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Disclosed herein are methods of treating autoimmune, allergic, and / or inflammatory diseases in a subject in need thereof, comprising administering a therapeutic agent comprising one or more antigen-binding sites on a cell involved in the autoimmune, allergic, and / or inflammatory diseases and depleting the cell.

N-[(S)-[3-[1-(2,2-difluoropropylcarbamoyl)-3-hydroxy-3-methyl- cyclobutyl]imidazo[1,2-b][1,2,4]triazin-6-yl]-[4-(trifluoromethyl)cyclohexyl]methyl]-4-5 methyl-1,2,5-oxadiazole-3-carboxamide, or a pharmaceutically acceptable salt and / or solvate thereof, being a potent modulator of human IL-17 activity, is accordingly of benefit in the treatment and / or prevention of various human ailments, including inflammatory and autoimmune disorders.

The utility model relates to a detection kit of autoimmune nervous system disease, including box and with box rotation connection's box cover, the inside position adjustable of box is provided with a plurality of baffle, the both sides of each baffle upper portion respectively symmetry is provided with a plurality of clamping block, moves the baffle, makes the clamping block between adjacent two baffles clamp test tube, each baffle top is equipped with the limiting structure for fixing its position, the inside one side of box evenly interval is provided with a plurality of card slot, the baffle one side has opened first recess, and the baffle upside has opened the second recess with first recess intercommunication, the limiting structure includes the clamping block for with first recess sliding fit and with clamping block vertical connection's operating block, the operating block is away from the inner wall between second recess between clamping block one side and first recess and is equipped with the compression spring. The detection kit of autoimmune nervous system disease can clamp test tube of different diameter size, and the scope of application is wider.

Provided herein are, among other things, methods for treating a patient suffering from an autoimmune disease.

The present invention relates to antigen-binding proteins, related fragments thereof, for binding to CD80, and their use for treating various conditions such as inflammation and autoimmunity.

This invention relates to MASP isotypes as inhibitors of complement activation. It also relates to novel ficolin-related peptides and peptides derived from these ficolin-related peptides for the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombosis, or coagulopathy, and for use as biomarkers. Furthermore, this invention relates to antibodies recognizing the novel ficolin-related peptides and peptides derived therefrom, nucleic acid molecules encoding the peptides, vectors for producing the peptides, and host cells.

The invention discloses a pig IFNAR2 protein mutant, which is characterized in that the 399th site in the amino acid sequence of the pig IFNAR2 protein is mutated from glycine to alanine, and the amino acid sequence of the pig IFNAR2 protein is as shown in SEQ ID NO. 1. The invention provides a specific cleavage site of ASFV protease pS273R, and the site is mutated through a gene editing technology so as to block the cleavage of pig IFNAR2 by the pS273R and improve the ability of pigs to resist African swine fever virus infection. By blocking ASFV from damaging type I IFN mediated JAK-STAT signal activation, on the basis of retaining pig autoimmune performance, higher specificity and higher efficiency are achieved, negative effects of genetic engineering on pig growth performance and reproductive performance can be greatly reduced, and biosafety is higher.

Provided herein are methods for generating extracellular vesicles (EVs) from massively cultured polarized DCs, as well as additional operations of separating CTLA-4 + EV and CTLA-4-EV from each other and recovering the two EV populations in a physically and functionally intact state; also provided is a composition comprising the EV obtained by the method. In addition, the use of CTLA-4-EV in the treatment of cancer, as well as the use of CTLA-4 + EV in the treatment of GVHD and other T cell mediated autoimmune conditions, is also provided.

The present application relates to a compound of formula (I) or formula (II), wherein L, R1, R2, R3 and R4 are as defined in the claims. The compounds of formula (I) or formula (II) are useful as medicaments for modulating SIK activity in autoimmune disorders, inflammation and other disorders. (I) and (II).

The invention relates to a construction method of an experimental autoimmune prostatitis rat model. The construction method comprises the following steps: S1, preparing a prostate specific antigen mixture; s2, selecting male SD rats as laboratory rats, and dividing the laboratory rats into a normal saline control group, a low-dose model group and a high-dose model group; s3, continuously injecting for 7 days, allowing the normal saline control group to accept injection of 0.2 ml of normal saline every day, allowing the low-dose model group to accept injection of 0.1 ml of prostate specific antigen mixture every day, and allowing the high-dose model group to accept injection of 0.2 ml of prostate specific antigen mixture every day; and S4, continuously feeding all groups of experimental mice to the 28th day, inducing the experimental mice in the low-dose model group and the high-dose model group by the prostate specific antigen mixture to cause experimental autoimmune prostatitis, and obtaining the experimental autoimmune prostatitis rat model. The use of animals can be reduced, the cost is reduced, and the modeling efficiency and stability can be improved.

The application discloses a polypeptide, the amino acid sequence of which is shown as SEQ ID NO: 1 or 2. The inventors find that the polypeptide has the following advantages: the recognized antigen epitope is clear, the cross-reaction is low, the selection of the antigen domain is more flexible and easy to synthesize, the cost is low, and the synthesis period is short by predicting the CXCR5 protein sequence. In addition, the polypeptide can be used for screening an anti-CXCR5 protein antibody, the obtained anti-CXCR5 protein antibody has strong binding capacity with the CXCR5 protein, the cost and period of developing the CXCR5 antibody drug can be effectively reduced, and a new strategy is provided for tumor and autoimmune disease treatment and disease diagnosis.

Disclosed herein are methods and systems for administering therapy to subjects who have been determined to display or not display a gene expression response signature established to distinguish between responsive and non-responsive prior subjects who have received the therapy. The subject and prior subjects may suffer from a disease, disorder, or condition for which it is desired to predict whether the subject will respond to the therapy. In an aspect, the disease, disorder, or condition may be an autoimmune disorder such as ulcerative colitis. The subject may be administered an anti-TNF therapy or an alternative to anti-TNF therapy based upon predictions provided by methods and systems described herein.

Described herein are compositions and methods of use thereof for reducing inhibiting B cell activation, B cell proliferation, the production of pathologic, autoimmune or interfering antibodies; and / or for eliciting humoral suppression and / or B cell tolerance in a subject in need thereof by contacting immune cells of the subject or donor immune cells in vivo and / or ex vivo with a composition comprising a Butyrophilin, optionally Butyrophilin A2, or a conjugate or fusion protein comprising said Butyrophilin. The methods include the use of butyrophilin A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2- related isoform, or a BTN2A2-related isoform fragment, or conjugates, and fusion polypeptides containing, preferably which comprise an Fc region comprising one or more mutations which reduce FcR binding and / or which suppress FcRN mediated clearance.

The present disclosure relates to methods related to the treatment of B-cell responsive autoimmune glomerulopathies.

The disclosure provides polypeptides that specifically bind to HLA-DQ8 for treating Type 1 Diabetes (TID) and methods using same for reducing autoimmune destruction of pancreatic islet beta cells. In particular, the present disclosure relates to peptides containing at least one D-amino acid that are capable of blocking the presentation of antigenic islet peptides (e.g., lnsB:9-23) by HLA-DQ8, and to their uses, especially as it relates to the prevention and / or treatment of TID.

Provided herein compositions and method of using chimeric antigen receptor (CAR) cell therapies for treating diseases or disorders, such as cancer or autoimmune disorders, including dual CARs that binds to both B-cell maturation antigen (BCMA) and CD19. Polynucleotides, vectors, host cells and methods for producing such dual CARs and cell therapies comprising the dual CARs are also provided herein.

This invention relates to an extracellular vesicle complex encapsulating thymosin β4, its preparation method, and its application. Mesenchymal stem cell small extracellular vesicles (MSC-sEVs) are extracted, mixed with thymosin β4 (Tβ4), and incubated. After ultrasound-assisted loading, MSC-sEVs-Tβ4 encapsulated in MSC-sEVs is obtained, which can be used in formulations or drugs targeting autoimmune dry eye. The beneficial effects of this invention are: by encapsulating Tβ4 in MSC-sEVs, the stability problem of Tβ4 in aqueous solution is effectively solved, allowing it to maintain its medicinal properties for a long time; furthermore, Tβ4 can synergistically interact with MSC-sEVs to produce a better therapeutic effect.

The present disclosure provides engineered extracellular vesicles (e.g., exosomes) comprising a fusion polypeptide that includes a Tumor Necrosis Factor-Stimulated Gene-6 (TSG-6) protein or a truncated form thereof displayed on the vesicle surface in a stabilized and biologically active configuration. The engineered extracellular vesicles retain or enhance the anti-inflammatory and cytoprotective activities of TSG-6 and may be used in the prophylaxis or treatment of inflammatory, autoimmune, or injury-related diseases or disorders. Also provided are nucleic acid constructs encoding the fusion polypeptide, compositions comprising the engineered extracellular vesicles, methods for producing the vesicles, and methods for using the vesicles in therapeutic applications.

The application relates to a method for constructing an experimental autoimmune prostatitis rat model, which comprises the following steps: S1, preparing a prostate specific antigen mixture; S2, selecting male SD rats as experimental rats and dividing the rats into a physiological saline control group, a low-dose model group and a high-dose model group; S3, continuously injecting for 7 days, wherein the physiological saline control group receives 0.2ml of physiological saline injection every day, the low-dose model group receives 0.1ml of the prostate specific antigen mixture injection every day, and the high-dose model group receives 0.2ml of the prostate specific antigen mixture injection every day; and S4, continuing to feed all the experimental rats in the groups until the 28th day, wherein the experimental rats in the low-dose model group and the high-dose model group are induced by the prostate specific antigen mixture to cause experimental autoimmune prostatitis, and an experimental autoimmune prostatitis rat model is obtained. The method can not only reduce the use of animals and the cost, but also improve the modeling efficiency and stability.

This invention discloses 6-substituted 2-([1,1'-biphenyl]-4-yl)quinoline-4-carboxylic acid analogs, which are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used to treat a variety of disorders and diseases where inhibition of DHODH may be clinically useful, including cancers such as hematologic cancers, including acute myeloid leukemia (AML), graft-versus-host disease, autoimmune disorders, and disorders associated with T-cell proliferation. When administered orally, the disclosed compounds exhibit flipped kinetics, i.e., pharmacokinetics in which the absorption rate, rather than the elimination rate, dominates the pharmacokinetic profile. The disclosed compounds exhibit sustained pharmacokinetic characteristics rather than immediate release characteristics. This summary is intended as a scanning tool for searching in a specific field and is not intended to limit this disclosure.

The present application belongs to the field of nutritional composition and biological medicine technology, and particularly relates to a composition for protecting and preserving liver, a preparation method, application and product thereof. The composition of the present application is composed of extract of Silybum marianum, glucoraphanin and extract of Cynara scolymus. The composition of the present application can intervene the pathological process of liver injury from multiple dimensions such as antioxidation, anti-inflammation, regulation of lipid metabolism and repair of hepatocytes through synergistic effect of the three components, significantly reduces the levels of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase, reduces the accumulation of liver fat, improves the antioxidant capacity of the body, effectively prevents or improves alcoholic, chemical, non-alcoholic fatty and autoimmune liver injury, delays the progression of liver fibrosis, and comprehensively maintains the structural integrity and functional stability of the liver.